Abstract: The invention relates to modulating the SIRP?-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRP? polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.

Abstract: The present invention relates to a drain plug for a sink. More specifically, the present invention provides a drain plug for a sink that includes an attached brush that may be utilized to clean dishes and other items in the sink. The device includes a drain plug configured to seal the drain of a sink. The drain plug may include apertures for straining solid materials and letting liquid flow out of the sink. The drain plug may also be a solid plug. An upper end of the drain plug includes a connector that removably secures a cleaning brush thereto. The cleaning brush has different configurations, such as handles for optional hand use. The connector of the drain plug is utilized to attach different cleaning brush types for different purposes.

Abstract: The present disclosure generally relates to the control of robotic end-effectors in order to manipulate objects. An exemplary method includes updating a classifier based on sensor data obtained at a first time and applying the updated classifier to second sensor data obtained at a second time, to assess status of a robotic end-effector with respect to one or more objects. The method further includes determining a robotic action based on the status assessed and causing a robotic device including the robotic end-effector to perform the robotic action.

Abstract: A gas delivery system is provided comprising an electrical backplane, a system controller operatively coupled to the electrical backplane, and a plurality of mass flow controllers. Each mass flow controller includes respective mass flow control circuitry operatively coupled to the electrical backplane. The system controller and each mass flow control circuitry are physically mounted on the electrical backplane. The gas delivery system further comprises a pump/purge system to help eliminate pressure build up in the system and provide a quick stop to a flow process in the system. Accordingly, a row associated with a flow process may be evaluated so that a mass flow controller may be swapped out as needed.

Abstract: The fluid control valve comprises: a valve seat constituting a part of a valve chamber; a valve body that is installed in the valve chamber and moves in a contacting/separating direction with respect to the valve seat; an actuator configured to move the valve body; and a plunger that transfers power of the actuator to the valve body. The valve body and the plunger are in contact with each other via an inclination suppressing protrusion configured to suppress an inclination of the plunger, the inclination being caused by contact between the valve body and the valve seat.

Abstract: There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a test sample from the subject selected from the group consisting of DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAAQ125. CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56; and (b) comparing expression of the at least 3 genes in the test sample with reference expression levels of the at least 3 genes from control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse survival.

Abstract: A gas delivery system is provided comprising an electrical backplane, a system controller operatively coupled to the electrical backplane, and a plurality of mass flow controllers. Each mass flow controller includes respective mass flow control circuitry operatively coupled to the electrical backplane. The system controller and each mass flow control circuitry are physically mounted on the electrical backplane. The gas delivery system further comprises a pump/purge system to help eliminate pressure build up in the system and provide a quick stop to a flow process in the system. Accordingly, a row associated with a flow process may be evaluated so that a mass flow controller may be swapped out as needed.

Abstract: A calibration data generation apparatus includes a flow rate sensor that measures the flow rate of a fluid flowing through a fluid control valve; a differential pressure control mechanism; a temperature control mechanism; and a control unit that when the fluid passing has sound velocity, uses the temperature control mechanism to change the temperature from a reference temperature to comparative temperature. In addition, the control unit includes a valve opening control part that controls the fluid control valve so that at the comparative temperature, an output value outputted from one of the position sensor and the flow rate sensor becomes equal to the reference output value of the one; and a calibration data generation part that generates the calibration data on the basis of a calibration data generation output value outputted from the other one of the position sensor and the flow rate sensor.

Abstract: Provided is a fluid control device that achieves high sealing performance at full closure, and can suppress damage to a valve body or a valve seat surface even without mechanical accuracy improvements. The fluid control device includes: a fluid control valve provided in a flow path through which fluid flows: and a control mechanism that controls the fluid control valve. The fluid control valve includes: a valve seat surface; a valve body that contacts and separates from the valve seat surface; and an actuator that drives the valve body. Further, the control mechanism includes a speed adjustment part that when the valve body is brought close to the valve seat surface in order to fully close the fluid control valve, and the valve seat surface and the valve body reach a predetermined distance apart, reduces the moving speed of the valve body more than before reaching the predetermined distance.

Abstract: The invention relates to modulating the SIRP?-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRP? polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.

Abstract: The present disclosure generally relates to the control of robotic end-effectors in order to manipulate objects. An exemplary method includes updating a classifier based on sensor data obtained at a first time and applying the updated classifier to second sensor data obtained at a second time, to assess status of a robotic end-effector with respect to one or more objects. The method further includes determining a robotic action based on the status assessed and causing a robotic device including the robotic end-effector to perform the robotic action.

Abstract: There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a test sample from the subject selected from the group consisting of DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAAQ125. CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56; and (b) comparing expression of the at least 3 genes in the test sample with reference expression levels of the at least 3 genes from control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse survival.

Abstract: The fluid control valve comprises: a valve seat constituting a part of a valve chamber; a valve body that is installed in the valve chamber and moves in a contacting/separating direction with respect to the valve seat; an actuator configured to move the valve body; and a plunger that transfers power of the actuator to the valve body. The valve body and the plunger are in contact with each other via an inclination suppressing protrusion configured to suppress an inclination of the plunger, the inclination being caused by contact between the valve body and the valve seat.

Abstract: A calibration data generation apparatus includes a flow rate sensor that measures the flow rate of a fluid flowing through a fluid control valve; a differential pressure control mechanism; a temperature control mechanism; and a control unit that when the fluid passing has sound velocity, uses the temperature control mechanism to change the temperature from a reference temperature to comparative temperature. In addition, the control unit includes a valve opening control part that controls the fluid control valve so that at the comparative temperature, an output value outputted from one of the position sensor and the flow rate sensor becomes equal to the reference output value of the one; and a calibration data generation part that generates the calibration data on the basis of a calibration data generation output value outputted from the other one of the position sensor and the flow rate sensor.

Abstract: There is described herein a method for improving or preserving hematopoietic stem cell (HSC) self-renewal during ex-vivo expansion of a population of cells comprising HSCs in an expansion medium, the method comprising culturing the population of cells in the presence of N-(4hydroxyphenyl)retinamide (4HPR).

Abstract: The invention relates to modulating the SIRP?-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRP? polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.

Abstract: Provided is a fluid control device that achieves high sealing performance at full closure, and can suppress damage to a valve body or a valve seat surface even without mechanical accuracy improvements. The fluid control device includes: a fluid control valve provided in a flow path through which fluid flows: and a control mechanism that controls the fluid control valve. The fluid control valve includes: a valve seat surface; a valve body that contacts and separates from the valve seat surface; and an actuator that drives the valve body. Further, the control mechanism includes a speed adjustment part that when the valve body is brought close to the valve seat surface in order to fully close the fluid control valve, and the valve seat surface and the valve body reach a predetermined distance apart, reduces the moving speed of the valve body more than before reaching the predetermined distance.

Abstract: The invention relates to modulating the SIRP?—CD47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided SIRP? antibodies and antibody fragments, preferably used for treating hematological cancer.

Abstract: This invention relates to human hematopoietic stem cells. Specifically the invention relations to the identification of single human hematopoietic stem cells capable of long-term multilineage engraftment and self-renewal. The invention also relates to an early lymphoid progenitor with monocytic potential, including dendritic cell potential.

Abstract: A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis.